Mundipharma AG
St. Alban-Rheinweg 74
Basel
CH-4006
Tel: 41-61-2051112
Fax: 41-61-2051109
42 articles about Mundipharma AG
-
Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and/or Invasive Candidiasis at ECCMID 2022
4/14/2022
Cidara Therapeutics, Inc. and Mundipharma today announced that the companies will present new clinical data and analyses of rezafungin, a novel, once-weekly echinocandin in development for the treatment of candidemia and invasive candidiasis and prevention of invasive fungal infections, at the 32nd European Congress of Clinical Microbiology and Infectious Diseases.
-
Clinical Catch-Up: August 16-20
8/23/2021
It was another busy week in clinical trial news. Here’s a look. -
Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
8/17/2021
Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Mundipharma today announced that the companies have completed recruitment of the pivotal Phase 3 ReSTORE trial evaluating the efficacy and safety of rezafungin as a potential first-line treatment for candidemia and invasive candidiasis.
-
Evaluate BETADINE® Antiseptic Products’ Effectiveness Against SARS-CoV-2
4/21/2020
Mundipharma announced that it will embark on an ambitious series of studies both in vitro and in vivo to evaluate the effectiveness of its BETADINE® antiseptic products against the novel coronavirus which causes COVID-19 disease.
-
Mundipharma Enters Partnership With Samsung Bioepis to Expand Biosimilars Into Hong Kong and Taiwan
1/13/2020
Mundipharma announced a partnership with Samsung Bioepis to commercialize Samsung Bioepis' first-wave biosimilar candidates in Taiwan and Hong Kong.
-
Mundipharma Announces Exclusive Deal for Biosolution's CartiLife(R) in South Korea
1/7/2020
Mundipharma has announced that it has sealed an exclusive sales agreement with Biosolution Co., Ltd, a Korea-based leader in cell-based biotechnology, to market and distribute its fourth-generation autologous chondrocyte implantation product, CartiLife®.
-
Sackler-Owned Mundipharma Uses Tactics Similar to Purdue in OxyContin Marketing in China, AP Repo...
11/21/2019
The AP report shows that in China, Mundipharma representatives are informing doctors that OxyContin is less addictive than other painkillers, which is a similar tactic the company used in the 1990s in the United States. -
Grunenthal and Mundipharma Enter Commercial Partnership in China
1/15/2018
Gruenenthal and Mundipharma announced today that they have entered into a License and Distribution Agreement.
-
Mundipharma Uses Thinfilm’s NFC Solution to Generate Consumer Awareness for New Cold-Prevention Medication
12/21/2017
Beginning in December, Mundipharma will leverage Thinfilm’s complete NFC solution to deploy and manage a consumer-focused mobile marketing campaign promoting its BETADINE Cold Defence nasal spray product.
-
Mundipharma Release: CHMP Positive Opinion For Opioid Dependence Treatment With Zubsolv (Buprenorphine And Naloxone) In Europe
9/18/2017
-
Mundipharma Receives CHMP Positive Opinion For Nyxoid (Intranasal Naloxone Spray)
9/15/2017
-
Vectura : Mundipharma Presents Positive Findings At ERS 2017
9/12/2017
-
Tiny Virtual Biotech CellAct Forges $250 Million Chemo R&D Pact With Mundipharma
8/15/2017
-
Mundipharma AG And Helsinn Expand Exclusive Licensing And Distribution Agreements For Leading Anti-emetic Products In Middle East, Africa, Latin America And Indonesia
2/14/2017
-
Mundipharma Research Release: Company Becomes Latest Life Sciences Organization To Implement New User Experience Version Of CSC’s FirstDoc RIM Application
1/18/2017
-
Mundipharma AG Signs New Deal With Vectura Limited For Global Development And Commercialization Of Inhaled Triple Therapy VR2076 For The Treatment Of Asthma And COPD
12/27/2016
-
Mundipharma AG Announces EU Regulatory Submission For Nyxoid
11/2/2016
-
Mundipharma AG And Orexo Announce EU Regulatory Submission For Zubsolv
10/4/2016
-
Manchester City Nets Key Partnership With Mundipharma AG
10/4/2016
-
Mundipharma AG Obtains Global (Ex-US) Rights To Orexo’s Opioid Dependence Treatment Zubsolv (Buprenorphine And Naloxone)
6/30/2016